Real-time HRMAS 13 C NMR of obligately anaerobic cells identifies new metabolic targets in the pathogen Clostridioides difficile
C Diff Drug Development
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021 - Business Wire
C. difficile Infection Therapeutic Drug Market to Witness ... C. difficile Infection Therapeutic Drug Market to Witness Growth Acceleration by Top Key Players – Pfizer Inc., Astellas ....
The C Diff Foundation Assures Patients C. diff. Clinical Trials Continue to Move Forward Safely - Northwest Georgia News
TAMPA, Fla., Jan. 11, 2021 (SEND2PRESS NEWSWIRE) –- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to
Microbome for c diff works
An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.
Destiny Pharma completes enrolment for XF-73 trial on schedule - Proactive Investors UK
XF-73 has been awarded both qualifying infectious disease product and Fast Track status by the US Food and Drug Administration
Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology - Valdosta Daily Times
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 6, 2021--
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium - BioSpace
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection (CDI).
Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II - Labiotech.eu
MGB Biopharma's antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence four weeks after.
MGB Biopharma - Successful End-of-Phase 2 Meeting with FDA for MGB-BP-3 a Potential New Gold Standard First-Line Treatment for Clostridioides difficile Infection (CDI) - PRNewswire
/PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing MGB-BP-3, a novel antibacterial, for the treatment of Clostridioides difficile (CDI),...
Destiny Pharma appoints C. difficile expert to its scientific advisory board - Proactive Investors UK
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1 open-label single-group trial - The Lancet
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: A phase 1 open-label single-group trial - MD Linx
Assessment of Nontraditional Products in Development to Combat Bacterial Infections March 2021 - The Pew Charitable Trusts
While antibiotic innovation—finding and designing new types of antibiotics and improving existing drugs—remains essential to combating antibiotic resistance, “outside-the-box” approaches to preventing and treating bacterial infections are also needed. Such nontraditional approaches encompass a variety of products.
Evogene's Subsidiary Biomica: Impressive Pre-Clinical Data For Its Microbiome Therapeutic BMC128 - Seeking Alpha
Evogene's subsidiary Biomica released impressive pre-clinical data for its clinical candidate BMC128. Read this article to learn more about what this means for the company.
Novel Antibiotic for C diff Enters Phase 2 Clinical Trial - Contagionlive.com
Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.
Cationic Homopolymers Inhibit Spore and Vegetative Cell Growth of Clostridioides difficile
A wide range of synthetic polymers have been explored for antimicrobial activity. These materials usually contain both cationic and hydrophobic subunits because these two characteristics are prominent among host-defense peptides. Here, we describe a series of nylon-3 polymers containing only cationi …
Innovative Microbiome-Based C. difficile Treatments in the Pipeline - Infectious Disease Special Edition
Destiny Pharma targets growth as anti-infection treatments return to prominence - Proactive Investors UK
With several potential treatments for serious infections currently in development, Destiny Pharma PLC has therefore found itself in an enviable position.
In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment of CDI ver …
Summit Therapeutics Announces Preclinical Candidate and - GlobeNewswire
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738...
Genome-based rational engineering of Actinoplanes deccanensis for improving fidaxomicin production and genetic stability
Microbial fermentation is currently still the major way to produce structural complicated clinical drugs. Yet, the low productivity and genetic instability of producing strains remain the bottlenecks in microbial pharmaceutical industry. Fidaxomicin is a microbial drug against the Clostridium diffic …
Metformin inhibited C. diff spread in three study models - Medical Xpress
Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021 - Business Wire
Identification of linear epitopes on the flagellar proteins of Clostridioides difficile
Our results open the possibility to use these epitopes as suitable anti-C. difficile vaccine antigens.
Innovative Microbiome-Based C. difficile Treatments in the Pipeline - Gastroenterology & Endoscopy News
Diabetes drug could protect against dangerous infection - EurekAlert
Researchers from Wake Forest School of Medicine in North Carolina have demonstrated that a common diabetes drug inhibits the spread of Clostridioides difficile, or C. diff -- a potentially life-threatening infection commonly acquired during hospital stays. The team will present their work virtually at the American Physiological Society's (APS) annual meeting at Experimental Biology 2021.
Strong Antimicrobial Effects of Xanthohumol and Beta-Acids from Hops against Clostridioides difficile Infection In Vivo
Clostridioides (C.) difficile is an important causative pathogen of nosocomial gastrointestinal infections in humans with an increasing incidence, morbidity, and mortality. The available treatment options against this pathogen are limited. The standard antibiotics are expensive, …
Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections
Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical d...
WHO: No antibiotic in development sufficiently addresses drug resistance - Healio
None of the 43 traditional antibiotics in the clinical pipeline that target WHO priority pathogens, Clostridioides difficile or tuberculosis sufficiently addresses drug resistance, according to a new report.WHO’s annual Antibacterial Pipeline Report reviews antibiotic candidates in early development or the clinical stages of testing to assess progress, identify gaps in drug resistance and